ITI-1001 not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.”In the company’s words, NCT05698199 on ClinicalTrials.gov
- Tested for
- Glioblastoma
- Main trialPhase 1
- “This Phase I clinical trial will evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of 8 mg ITI-1001 in participants with newly diagnosed glioblastoma (GBM).”In the company’s words, NCT05698199 on ClinicalTrials.gov
Other drugs for Glioblastoma
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- LAM561Laminar Pharmaceuticals · Phase 2/3
- VebreltinibBeijing Pearl Biotechnology Limited Liability Company · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 11 Feb 2026 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026